Product for Out-licensing
- Overview
- Product Profile
- Data
- News
Cyclobenzaprine ER (once-daily)
The first and only once-a-day formulation of cyclobenzaprine, the most-prescribed muscle relaxant in the U.S.1 Developed and manufactured by Eurand.
Eurand utilizes their proprietary Diffucaps® technology to create a convenient, once-daily extended release formulation of cyclobenzaprine with an improved side effect profile; Eurand’s cyclobenzaprine ER shows lower rates of somnolence, a common side effect of muscle relaxants.
Eurand currently out-licenses cyclobenzaprine ER in several major markets around the world. It is marketed in the U.S. as AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) by Cephalon.
Therapeutic Category |
Pain |
Indication |
Skeletal muscle relaxant: relief of muscle spasm associated with acute and painful musculoskeletal conditions |
Development Status |
Commercialized; Licensing opportunities available |
Available Dosage Strength(s) |
|
Product Description |
Novel, once-daily formulation of the skeletal muscle relaxant, cyclobenzaprine hydrochloride |
Eurand Technology |
Diffucaps® - Customized Drug Release technology |
Licensing Opportunities |
Eurand is seeking licensing partners in Asia Pacific territories. Marketing Authorizations are also available in a number of EU major markets. |
Cyclobenzaprine ER eliminates the multiple peaks and troughs in daily plasma levels associated with the IR formulation.2
Single-day, crossover pharmacokinetic study: Mean cyclobenzaprine concentration over time (N-36).
06/2008 |
Cyclobenzaprine ER: Development of the First Once-Daily Muscle By: Troy Harmon, MS, MBA |
Eurand has partnered with countries worldwide to commercialize, license, and supply cyclobenzaprine ER:
- U.S.: Marketed by Cephalon as AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules)
- South Korea: Marketed by Daewoong Pharmaceuticals Co., Ltd.as Bonelax®
- Turkey: Nobel Ilac A.S.
- Israel: PharmaSwiss SA
- South Africa: Adcock Ingram
- South America: Tecnofarm SA
This information is provided solely for the purpose of the evaluation of business opportunities by potential collaboration partners. The information is based on currently existing data and marketing authorizations in a number of jurisdictions and should not be assumed to be approved by regulatory authorities in any individual country. Consumers should consult with their individual physician for product information and should not rely upon any information provided here.
For more information on this product, please contact Eurand.
1IMS MAT Aug 2008.
2Adapted from: Darwish et al. Clin Drug Investig. 2008.
AMRIX is a registered trademark of Cephalon in the U.S.
Contact Us
Click here to request moreinformation on Eurand's
Products for Out-Licensing
Pain Products
Customized Drug Release
Pharmaceutical technologies for formulation development and life cycle management solutions.
Click Now